Stockreport

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Myriad Genetics, Inc.  (MYGN) 
Last myriad genetics, inc. earnings: 2/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: myriad.com/news-center/investor-information
PDF SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announce [Read more]